Effect of aging on healthcare costs of inflammatory bowel disease: A glimpse into the future

Inflammatory Bowel Diseases

Volumn 20, Issue 4, 2014, Pages 637-645

  Van Der Have, Mike ^a   Mangen, Marie Josée J ^a   Van Der Valk, Mirthe E ^a   Smeets, Hugo M ^a,b   Van Bodegraven, Ad ^c   Dijkstra, Gerard ^d   Fidder, Herma H ^a   De Jong, Dirk J ^e   Pierik, Marieke ^f   Ponsioen, Cyriel Y ^g   Van Der Meulen De Jong, Andrea E ^h   Van Der Woude, Ca Janneke ⁱ   Van De Meeberg, Paul C ^j   Romberg Camps, Mariëlle J L ^k   Clemens, Cees H M ^l   Jansen, Jeroen M ^m   Mahmmod, Nofel ⁿ   Bolwerk, Clemens J M ^o   Vermeijden, J Reinoud ^p   Siersema, Peter D ^a   Leenders, Max ^a   Oldenburg, Bas ^a   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Agis Health Insurance   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j SLINGELAND HOSPITAL   (Netherlands)

^k Zuyderland Medical Centre   (Netherlands)

^l Department of Gastroenterology and Hepatology Orbis Medical Center ^*  (Netherlands)

^m ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁿ ST ANTONIUS HOSPITAL   (Netherlands)

^o REINIER DE GRAAF HOSPITAL   (Netherlands)

^p MEANDER MEDICAL CENTER   (Netherlands)

more..

Author keywords

Aging; Elderly persons; Healthcare costs; Inflammatory bowel disease

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ADULT DISEASE; AGED; AGING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; STEROID THERAPY; ADOLESCENT; AGE; ECONOMICS; FORECASTING; HEALTH SERVICE; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; POPULATION DYNAMICS; QUESTIONNAIRE; TRENDS; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; COST OF ILLNESS; EFFICIENCY; FEMALE; FORECASTING; HEALTH CARE COSTS; HEALTH SERVICES; HEALTH TRANSITION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NETHERLANDS; PREVALENCE; QUESTIONNAIRES; YOUNG ADULT;

EID: 84898761661     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000442677.55051.03     Document Type: Article

References (57)

1. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol. 2006;18:601-606.
2. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol. 2006;12:75-81.
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
4. Van der Valk ME, Mangen MJ, Leenders M; on behalf COIN study group and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut. 2014;63:72-79.
5. Piront P, Louis E, Latour P, et al. Epidemiology of inflammatory bowel diseases in the elderly in the province of Leige. Gastroenterol Clin Biol. 2002;26:157-161.
6. Proj-10c2150p [databae online] Giampaolo Lanzieri: Eurostat, statistical office of the European Union; 2012. Update March 6, 2012.
7. Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606-613.
8. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182-189.
9. Kaplan RM, Babad YM. Balancing influence between actors in healthcare decision making. BMC Health Serv Res. 2011;11:85.
10. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14:309-317.
11. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992;14:318-327.
12. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32:1134-1139.
13. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary Care University Hospital. Am J Gastroenterol. 2000;95:677-683.
14. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49-57.
15. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471-1478.
16. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719-728.
17. Enthoven AC, van de Ven WP. Going Dutch-managed-competition health insurance in the Netherlands. N Engl J Med. 2007;357:2421-2423.
18. Tsiachristas A, Hipple-Walters B, Lemmens KM, et al. Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy. 2011;101:122-132.
19. Van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235-240.
20. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2011; 106:319-328.
21. Timmer A, Kemptner D, Takses A, et al. A survey based index was validated for measuring disease activity in inflammatory bowel disease. An evaluation study. J Clin Epidemiol. 2009;62:771-778.
22. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990;336:16-19.
23. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J. 1959;1:387-394.
24. Salén BA, Spangfort EV, Nygren AL, et al. The disability rating index: an instrument for the assessment of disability in clinical settings. J Clin Epidemiol. 1994;47:1423-1435.
25. König HH, Ulshöfer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1205-1215.
26. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96: 804-810.
27. Russel MG, Pastoor CJ, Brandon S, et al. Validation of the Dutch translation of the inflammatory bowel disease questionnaire (IBDQ): a health-related quality of life questionnaire in inflammatory bowel disease. Digestion. 1997;58:282-288.
28. Hakkaart-van Roijen L. Manual for Costing: Methods and Reference Prices for Economic Evaluations in Healthcare [Health Care Insurance Board Website]. 2010. Available at: http://www.cvz.nl/binaries/hst% 3Ahst/hst%3Asites/zinl-www/ hst%3Acontent/pakket/werkwijze-pakketbeheer/ beoordeling-geneesmiddelen/farmaco- economisch-onderzoek/farmacoeconomisch- onderzoek/farmaco-economisch-onderzoek/ zinl%3Aparagraph% 5B3%5D/zinl%3Adocuments/1007-handleiding-voor-kostenonderzoek/ Handleiding+voor+kostenonderzoek.pdf. Accessed June 9, 2013.
29. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol. 2011;64:424-430.
30. Prognosis census; gender, age, country of origin and generation, 2013-2060 [Database online]. Joop Beer: Statistical office of the Netherlands; 2012. Updated December 13, 2012.
31. Consumer prices; price index 2006 = 100 [Database online]. Joop Beer: Statistical office of the Netherlands; 2012. Update January 9, 2014.
32. Luijben AHP, Kommer GJ. Tijd en Toekomst. Deelrapport van de Volksgezondheid Toekomst Verkenning 2010 Van Gezond naar Beter. RIVM-rapport 270061008. Bilthoven, the Netherlands: RIVM; 2010.
33. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408-2415.
34. Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:878-889.
35. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63: 423-432.
36. Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:62-68.
37. Heresbach D, Alexandre JL, Bretagne JF, et al. Crohn's disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol. 2004;16:657-664.
38. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5-13.
39. Ha CY, Newberry RD, Stone CD, et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8:682-687.e1.
40. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30-35.
41. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
42. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4: 1017-1024.
43. Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18:1498-1508.
44. Longobardi T, Bernstein CN. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol. 2007;102:1683-1691.
45. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519-525.
46. Okunade AA, Murthy VNR. Technology as 'major driver' of health care costs: a cointegration analysis of the newhouse conjecture. J Health Econ. 2002;21:147-159.
47. Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff (Millwood). 1994;13:28-46.
48. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61:918-932.
49. Gecse KB, Khanna R, van den Brink GR, et al. Biosimilars in IBD: hope or expectation? Gut. 2013;62:803-807.
50. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol. 2009;6:550-552.
51. Keith J. Fontenot. S1695: biologics price competition and innovation Act of 2007 Congressional Budget Office cost estimate [Congressional Budget Office Website]. June 25, 2008. Available at: http://www.cbo.gov/ftpdocs/ 94xx/doc9496/s1695.pdf. Accessed June 9, 2013.
52. Sleijpen G. Home Internet access rate highest in the Netherlands [Statistical office of the Netherlands, Website]. June 18, 2012. Available at: http:// www.cbs.nl/enGB/menu/themas/dossiers/eu/publicaties/archief/2012/2012- 3636-wm.htm. Accessed June 9, 2013.
53. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004;57:131-141.
54. Burisch J, Jess T, Martinato M, et al; on behalf of ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7: 322-337.
55. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-1517.
56. Radovits BJ, Fransen J, Eijsbouts A, et al. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:906-910.
57. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006; 65:1226-1229.